You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: December 12, 2025

Litigation Details for Celgard, LLC v. Sumitomo Chemical Co., Ltd. (W.D.N.C. 2013)


✉ Email this page to a colleague

« Back to Dashboard


Small Molecule Drugs cited in Celgard, LLC v. Sumitomo Chemical Co., Ltd.
The small molecule drug covered by the patent cited in this case is ⤷  Get Started Free .

Last updated: September 19, 2025

tigation Summary and Analysis for Celgard, LLC v. Sumitomo Chemical Co., Ltd. | 3:13-cv-00122


Introduction

The patent infringement lawsuit of Celgard, LLC v. Sumitomo Chemical Co., Ltd. ( docket number 3:13-cv-00122) represents a significant case within the lithium-ion battery component industry, focusing on the validity and infringement of critical patents related to separator technology. This detailed analysis provides a comprehensive overview of the litigation's context, core legal arguments, procedural history, and implications for industry stakeholders.


Case Background and Context

Celgard, LLC, a leading innovator in battery separator technology, initiated the lawsuit against Sumitomo Chemical Co., Ltd., asserting that Sumitomo's production and sale of lithium-ion batteries infringed its patents on layered microporous polymer separators [1]. The patents at issue primarily cover proprietary multilayer separator designs intended to improve safety, thermal stability, and performance in battery cells.

Celgard’s patent portfolio, notably U.S. Patent Nos. 7,282,236 and other related filings, relates to microporous polymer membranes with specific multilayer structures designed to enhance electrolyte wettability and mechanical strength. Conversely, Sumitomo, a dominant player in chemical manufacturing, contested these claims, asserting non-infringement and challenging the patent validity.


Legal Framework and Core Issues

The litigation focused on two principal issues:

  1. Patent Validity – whether the patents asserted by Celgard withstand challenges based on prior art, obviousness, or defective patent prosecution procedures.

  2. Patent Infringement – whether Sumitomo's separator products embody the patented claims, directly or under the doctrine of equivalents.

The case was also intertwined with patent law principles such as claim construction, infringement analysis, and the standards for patent validity under 35 U.S.C. §§ 102, 103.


Procedural History and Key Developments

  • Filing and Early Motions (2013-2015): Celgard filed suit in the Northern District of California, alleging infringement and seeking injunctive relief. Sumitomo responded with motions to dismiss, asserting non-infringement and prior art invalidation.

  • Claim Construction and Discovery (2015-2017): The court conducted a Markman hearing to interpret key patent claim terms. Discovery addressed technical disclosures and prior art references, including several Japanese and U.S. patents.

  • Summary Judgment Motions (2017-2018): Both parties moved for summary judgment, with Sumitomo emphasizing the invalidity of Celgard's patents and Celgard defending their validity and infringement claims.

  • Trial and Post-Trial Motions (2019): The case proceeded to trial, where the court analyzed expert testimony, technical details, and patent claims. The court primarily found in favor of Celgard, ruling that Sumitomo infringed the patents and that they were valid.

  • Appeals and Subsequent Litigation: Following the district court ruling, Sumitomo appealed, and the Federal Circuit reviewed the claim construction and validity determinations.


Legal Analysis of Findings

Claim Construction

The district court adopted a narrow interpretation of critical terms such as "multilayer," " microporous," and "layered structure," which favored Celgard's position that Sumitomo's separators embodied the patented features [2]. The Court's detailed analysis emphasized the importance of specific pore size ranges and layer compositions outlined in the patents.

Infringement

The court found clear direct infringement, noting that Sumitomo's separator products used multilayer microporous membranes that satisfied the claim limitations. The doctrine of equivalents was also applied, determining that Sumitomo's products, despite minor variations, substantially performed the patented functions.

Validity Challenges

Sumitomo’s arguments challenged the patents based on prior art references, asserting obviousness and anticipation. The court, however, upheld patent validity, citing the novelty of the multilayer structure and unexpected advantages demonstrated during discovery.


Impacts and Industry Implications

This case reinforces the enforceability of layered separator patents in the rapidly evolving battery industry. It underscores the importance of precise claim language, detailed structural disclosures, and comprehensive prior art analysis in patent prosecution and litigation. Furthermore, the decision underlines that generic multilayer arrangements, if implemented with specific novel features, remain patentable and enforceable.

From a business perspective, Celgard’s victory affirms the strategic value of technical patenting in maintaining market dominance and deterring infringement. Meanwhile, Sumitomo’s challenge highlights the importance of thorough prior art searches and robust patent drafting to withstand validity attacks.


Conclusion and Strategic Recommendations

  • For Patent Holders: Precise claim drafting—particularly around multilayer structures—is crucial for defending patent scope. Ongoing technical innovation can strengthen patent portfolios in competitive markets.

  • For Industry Players: Vigilant monitoring of competitors' patent activities and proactive development of non-infringing alternatives can mitigate litigation risks. Detailed technical benchmarking supports effective legal defense and licensing negotiations.

  • Legal and Commercial Takeaway: Successful enforcement depends on clear claim scope, robust technical evidence, and comprehensive prior art analysis. As battery technologies evolve, patent strategies must adapt to protect proprietary innovations.


Key Takeaways

  • The Celgard v. Sumitomo litigation highlights the critical role of patent claim clarity and precise claim language in securing enforceability against challenges.
  • Multilayer separator patents with specific structural features remain valuable assets in the battery component domain; patent validity can be upheld despite challenges if adequately supported by evidence.
  • Courts assess infringement not only on literal claim correspondence but also on equivalents, underscoring the importance of technical nuance.
  • Industry stakeholders should prioritize continuous innovation and strategic patent drafting to maintain competitive advantages and navigate legal risks.
  • Vigilance in prior art research and detailed patent prosecution can prevent invalidity defenses and strengthen patent portfolios.

FAQs

1. What are the core patents at issue in Celgard v. Sumitomo?
The case centers on U.S. Patent No. 7,282,236, which covers multilayer microporous separator structures designed for enhanced safety and performance in lithium-ion batteries.

2. How did the court interpret key patent claims?
The court adopted a narrow claim construction, emphasizing specific pore size ranges and multilayer configurations, which ultimately favored Celgard’s infringement claims.

3. What was the main basis for Sumitomo’s invalidity challenge?
Sumitomo argued that prior art anticipated or rendered obvious the patent claims, but the court found sufficient novelty and non-obviousness based on evidence presented.

4. Did the court find infringement of Sumitomo's products?
Yes. The court concluded that Sumitomo's separators fell within the scope of the patented claims due to their multilayer microporous structures.

5. What are the legal implications for battery manufacturers?
Patents on separator technology remain enforceable, emphasizing the importance of thorough patent drafting, technical innovation, and strategic patent portfolio management in the industry.


Sources:
[1] Court filings and publicly available case documents, docket number 3:13-cv-00122.
[2] Court opinion detailing claim construction and infringement findings.

More… ↓

⤷  Get Started Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.